| 產(chǎn)品名稱 | Cryptococcus neoformans (Sanfelice) Vuillemin |
|---|---|
| 商品貨號 | B220032 |
| Deposited As | Cryptococcus neoformans (Sanfelice) Vuillemin, anamorph |
| Strain Designations | MCC1 |
| Alternate State | Filobasidiella neoformans Kwon-Chung |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format | frozen |
| Storage Conditions | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Type Strain | no |
| Antigenic Properties | serotype A, serotype A
Ref  Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 |
| Preceptrol® | no |
| Medium | ATCC® Medium 1245: YEPD |
| Growth Conditions | Temperature: 30.0°C |
| Name of Depositor | J Heitman |
| Special Collection | NCRR Contract |
| Isolation | derived from M049 by disrupting the FRR1 gene |
| References | Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
